Review of Abortion Pill Safety Announced by Government Following Concerning Studies

Share this report on Facebook, Twitter, or print it using . The share links are activated using a script that encodes the URL and sets it to the share links.

The report reveals that more than 1 in 10 women experience negative effects from chemical abortions. The U.S. Food and Drug Administration (FDA) has confirmed it will review the abortion drug mifepristone after recent studies have questioned its safety.

FDA Commissioner Marty Makary is “committed” to the review. This follows a pledge made by U.S. Secretary of Health and Human Services Robert Kennedy Jr., who instructed Makary to conduct a “complete review” of the abortion pill after findings indicated that more than 1 in 10 women experience adverse side effects from chemical abortions.

The report is based on a study that used public health insurance records and found that about 11% of women suffer at least one “serious adverse event” within 45 days of taking mifepristone. Of the total patients studied, more than 4.7% wound up in the emergency room, more than 3.3% suffered hemorrhaging, and more than 1.3% got an infection. Thousands of women were hospitalized, with more than 1,000 needing blood transfusions.

Pro-life advocates have celebrated the confirmation of the review. Meanwhile, the Charlotte Lozier Institute has challenged the claim that medication abortion is “safer than Tylenol.”

This article was republished with permission from the National Catholic Register.